← Back to Search

Monoclonal Antibodies

dupilumab for Eczema (NEURADAD Trial)

Phase 4
Waitlist Available
Research Sponsored by Regeneron Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at week 16
Awards & highlights

NEURADAD Trial Summary

This trial has two parts. In Part A, they are testing how well a certain test can measure cognitive function in teens with moderate to severe AD. In Part B, they are testing how well dupilumab (a medication) works in improving cognitive function in teens with moderate to severe AD.

Eligible Conditions
  • Eczema

NEURADAD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and at week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean change from baseline in Conner's CPT-3 d' T-score
Proportion of AD patients with a Conner's CPT-3 d' T-score ≥ 60
Secondary outcome measures
Correlation of change in AD disease severity based on BSA with AASP Sensory Sensitivity Summary Score
Correlation of change in AD disease severity based on BSA with change in Conners' CPT-3 score
Correlation of change in AD disease severity based on CDLQI with AASP Sensory Sensitivity Summary Score
+38 more

Side effects data

From 2022 Phase 3 trial • 133 Patients • NCT04417894
24%
Nasopharyngitis
16%
COVID-19
10%
Upper respiratory tract infection
9%
Dermatitis atopic
6%
Blood creatine phosphokinase increased
1%
Metastases to lung
1%
Post procedural infection
1%
Adenocarcinoma of colon
1%
Syncope
1%
Dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Matching Placebo
Dupilumab Q2W

NEURADAD Trial Design

2Treatment groups
Experimental Treatment
Group I: Part BExperimental Treatment1 Intervention
Patients in Part A may also enroll in Part B provided they meet the eligibility criteria.
Group II: Part AExperimental Treatment0 Interventions
Assessed in a single visit and no study-related treatment will be given.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
dupilumab
2022
Completed Phase 4
~330

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsLead Sponsor
615 Previous Clinical Trials
379,802 Total Patients Enrolled
34 Trials studying Eczema
13,173 Patients Enrolled for Eczema
SanofiIndustry Sponsor
2,163 Previous Clinical Trials
3,512,435 Total Patients Enrolled
41 Trials studying Eczema
15,736 Patients Enrolled for Eczema
Clinical Trial ManagementStudy DirectorRegeneron Pharmaceuticals
259 Previous Clinical Trials
250,999 Total Patients Enrolled
20 Trials studying Eczema
10,702 Patients Enrolled for Eczema

Media Library

dupilumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT05203380 — Phase 4
Eczema Research Study Groups: Part A, Part B
Eczema Clinical Trial 2023: dupilumab Highlights & Side Effects. Trial Name: NCT05203380 — Phase 4
dupilumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05203380 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In which geographical locations can participants access this research project?

"The trial is accepting patients at nine medical centres, including Chicago and Miami. To reduce travel commitments, it's best to select the nearest clinic for enrollment purposes."

Answered by AI

Are there available openings for participants in this exploration?

"Affirmative, the information on clinicaltrials.gov suggests that this medical trial is actively seeking patients, having been initially posted to the website in late January 2022 and last updated in October of that year. 82 individuals are needed across 9 different sites for successful completion."

Answered by AI

What objectives is this trial attempting to accomplish?

"The primary end-point of this day 1 evaluation is the mean alteration in Conner's CPT-3 d' T-score. Secondary outcome metrics include a correlation between Stroop Interference Score and disease severity according to PROMIS Pediatric Sleep Disturbance Questionnaire, Correlating Conners’ CPT-3 scores with AD illness intensity using Hospital Anxiety & Depression Scale (HADS), and gauging Adult/Adolescent Sensory Profile (AASP) Sensitivity Scores against AD seriousness by EASI metric."

Answered by AI

Has the Federal Drug Administration given approval to dupilumab?

"Dupilumab has been approved, so it was assessed a score of 3 on our team's scale. This is because this medical intervention is currently in Phase 4 trials."

Answered by AI

Does this study accept participants under the age of 20?

"This clinical trial is designed for adolescent patients aged 12 to 17 and contains 101 trials specifically for minors. There are also 165 trials geared towards people over 65 years old."

Answered by AI

Am I eligible to join the experiment?

"Candidates who have infantile eczema and are aged between 12-17 can volunteer for this medical trial. The recruitment quota stands at 82 participants."

Answered by AI

What is the participant cap for this clinical experiment?

"Affirmative, according to clinicaltrials.gov this medical trial is open for recruitment. The study was initiated on January 27th 2022 and has been recently revised on October 11th 2022. In total 82 individuals have to be enrolled from 9 distinct sites of operation."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
2022. "Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05203380.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top